4//SEC Filing
Davidson Michael H. 4
Accession 0001573785-26-000001
CIK 0000034956other
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 9:49 PM ET
Size
14.0 KB
Accession
0001573785-26-000001
Insider Transaction Report
Form 4
Davidson Michael H.
Director
Transactions
- Award
Stock Option (right to buy)
2026-01-09+30,000→ 30,000 totalExercise: $13.30From: 2027-01-09Exp: 2036-01-09→ Common Stock (30,000 underlying)
Holdings
- 2,881
Common Stock
- 4
Stock Option (right to buy)
Exercise: $3200.00From: 2022-06-10Exp: 2031-06-10→ Common Stock (4 underlying) - 4
Stock Option (right to buy)
Exercise: $992.00From: 2023-06-09Exp: 2032-06-09→ Common Stock (4 underlying) - 100,000
Stock Option (right to buy)
Exercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (100,000 underlying) - 80,000
Stock Option (right to buy)
Exercise: $5.75From: 2026-07-01Exp: 2035-07-01→ Common Stock (80,000 underlying) - 47,500
Pre-Funded Warrant
[F1]Exercise: $0.01From: 2024-08-08→ Common Stock (47,500 underlying) - 25,000
Warrant
[F2]Exercise: $4.50From: 2024-08-08→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]The pre-funded warrant has no expiration date.
- [F2]The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact|2026-01-13
Documents
Issuer
TENAX THERAPEUTICS, INC.
CIK 0000034956
Entity typeother
Related Parties
1- filerCIK 0001573785
Filing Metadata
- Form type
- 4
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 9:49 PM ET
- Size
- 14.0 KB